Premium
Oral lactoferrin inhibits growth of established tumors and potentiates conventional chemotherapy
Author(s) -
Varadhachary Atul,
Wolf Jeffrey S.,
Petrak Karel,
O'Malley Bert W.,
Spadaro Michela,
Curcio Claudia,
Forni Guido,
Pericle Federica
Publication year - 2004
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/ijc.20271
Subject(s) - lactoferrin , chemotherapy , medicine , oral administration , pharmacology , cell growth , cd8 , cancer research , immunology , immune system , biology , biochemistry
In this work, we investigated the anticancer activity of orally administered recombinant human lactoferrin (rhLF) alone and in combination with chemotherapy in tumor‐bearing mice. rhLF inhibited the growth of squamous cell carcinoma (O12) tumors in T cell–immunocompromised nu/nu mice by 80% when administered at 1,000 mg/kg (2.9 g/m 2 ) by oral gavage twice daily for 8 days ( p < 0.001). Similar activity was observed in syngeneic, immunocompetent BALB/c mice, where orally administered rhLF (1,000 mg/kg, 2.9 g/m 2 once daily) halted the growth of mammary adenocarcinoma TUBO. Oral rhLF (200 mg/kg, 0.57 g/m 2 ) was also used alone and in combination with cis‐platinum (5 mg/kg) to treat head‐and‐neck squamous cell carcinoma in a syngeneic murine model. Monotherapy with oral rhLF or cis‐platinum caused 61% or 66% tumor growth inhibition over placebo, respectively. Mice receiving both therapies showed 79% growth inhibition, a statistically significant improvement over each drug alone. We then demonstrated that administration of oral rhLF (300 mg/kg, 0.86 g/m 2 ) to tumor‐bearing or naive mice resulted in (i) significantly increased production of IL‐18 in the intestinal tract, (ii) systemic NK cell activation and (iii) circulating CD8 + T‐cell expansion. These data suggest that oral rhLF is an immunomodulatory agent active against cancer as a single agent and in combination chemotherapy, exerting its systemic effect through stimulation of IL‐18 and other cytokines in the gut enterocytes. rhLF has been administered orally to 211 people without a single serious drug‐related adverse event. Thus, rhLF shows promise as a safe and well‐tolerated novel immunomodulatory anticancer agent. © 2004 Wiley‐Liss, Inc.